Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

How are biosimilar drugs affected by health reform?

Donald J. Palmisano, MD, JD
Meds
August 6, 2012
23 Shares
Share
Tweet
Share

The section of the Affordable Care Act, which calls for the creation of the biosimilar pathway, was recently upheld by the Supreme Court.  While not as headline-worthy as the news surrounding the individual mandate, the fact that the Biologics Price Competition and Innovation Act (BPCIA) provision survived the process was significant for the biotech world.

Biologics are some of the best treatment options for serious medical conditions such as cancer, autoimmune diseases, and Alzheimer’s.  Unlike traditional chemical drugs, biologics are made from living organisms and are significantly more complex.

Generic versions of chemically produced drugs have existed in the United States since the 1980’s, but copycat forms of biologic drugs are currently unavailable. In 2010 Congress tasked the Food and Drug Administration (FDA) with creating an approval pathway for the sale of biosimilar versions of biologic medicines in the United States, as part of the Affordable Care Act.

Although I believe that many parts of the Affordable Care Act are bad and will weaken care in the United States, the FDA’s ability to approve biosimilars will foster investment, ensure patient safety, expand patient access to biotech medicines.  Most importantly, the FDA will continue its work to develop a regulatory pathway for safe and effective use of biosimilars.

One challenge for regulators remains patient safety. Because biologics are made from living organisms, biosimilars can only be similar to their innovator product, never identical. Consequently, these copycat drugs can present safety challenges above and beyond traditional chemical drugs.

Any small difference in the structure or makeup of a biosimilar may cause serious side effects, if not properly regulated. Therefore, the FDA cannot take shortcuts. The FDA should include robust clinical testing for biosimilars, unique product names, labels and codes, as well as a means to track and trace these advanced medicines.  Additionally, requiring a tracing system will make it easier to identify and remove a faulty product from the pharmacy shelves and medicine cabinets.

Moving forward, the FDA must take into consideration all the possible safety risks.  For instance, allowing for a biosimilar to be exchanged for its biologic counterpart could cause severe safety consequences for the patients and could also take the health care decision making process out of the hands of patients and physicians and into the hands of insurers.  In addition, allowing pharmacists to provide biosimilars to patients who have been prescribed biologics can be dangerous due to the vital differences between biologics and their imitators. If patients are to be properly protected, federal and state lawmakers across America must ensure that switches of this kind are never made without the prescribing physician’s knowledge and consent.

As a long time patient advocate and surgeon, I know that the decision for health care should always be in the hands of qualified medical professionals and their patients. And, with the creation of biologic and biosimilar medicines standing out as some of the most important health care developments of our time, the FDA must work to ensure that these drugs continue to be held to the highest standards that protect patients from harm.

Donald J. Palmisano is the former president of American Medical Association and is Clinical Professor of Surgery and Clinical Professor of Medical Jurisprudence, Tulane University School of Medicine.

Prev

Moral professionalism should include advocacy and duty

August 6, 2012 Kevin 3
…
Next

Patients and physicians often forget that time is our friend

August 7, 2012 Kevin 5
…

Tagged as: Medications, Primary Care

Post navigation

< Previous Post
Moral professionalism should include advocacy and duty
Next Post >
Patients and physicians often forget that time is our friend

More by Donald J. Palmisano, MD, JD

  • People remember stories in your speech. The rest fades away.

    Donald J. Palmisano, MD, JD

More in Meds

  • The deadly consequences of a shortage: The Pluvicto crisis leaves metastatic prostate cancer patients in limbo

    Matt Drewes
  • The real story of Xylazine contamination in street fentanyl and how we can manage it

    Julie Craig, MD
  • The cannabis education gap: Why patients are left in the dark

    Timothy Byars
  • Are doctors ready to discuss psychedelic therapies with patients?

    Thaís Salles Araujo, MD
  • The rise and dark side of fungi: Exploring health benefits and pathogenic threats

    Sandra Vamos, EdD and Deanna Lernihan, MPH
  • Advocacy and collaboration lead to major patient safety benefits on sterile pharmaceutical compounding: a review of USP’s revisions to Chapter <797>

    Elizabeth Rebello, MD
  • Most Popular

  • Past Week

    • A patient’s perspective on the diminishing relationship between doctors and patients

      Michele Luckenbaugh | Conditions
    • Unmasking wage disparity in health care: the truth behind the Elmhurst Hospital physician strike

      Kevin Pho, MD | KevinMD
    • Why affirmative action is crucial for health equity and social justice in medicine

      Katrina Gipson, MD, MPH | Policy
    • How electronic health records preserve patients’ legacies in the words of oncologists

      Marc Braunstein, MD, PhD | Physician
    • Unmasking the brutal reality of gun violence in America: a call to action for unity and meaningful change

      Osmund Agbo, MD | Policy
    • Emulating Michael Jordan’s winning mindset: a path to success for health care professionals and entrepreneurs

      Harvey Castro, MD, MBA | Physician
  • Past 6 Months

    • The growing threat to transgender health care: implications for patients, providers, and trainees

      Carson Hartlage | Policy
    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
  • Recent Posts

    • Why doctors aren’t to blame for the U.S. opioid crisis [PODCAST]

      The Podcast by KevinMD | Podcast
    • Raw humanity on night float: inspiring patient encounters and overcoming challenges

      Johnathan Yao, MD, MPH | Physician
    • Is AI the solution for the shortage of nephrologists? ChatGPT weighs in.

      Amol Shrikhande, MD | Tech
    • Unlocking the secrets of cancer conferences: an end-of-life counselor’s journey among pharmaceutical giants

      Althea Halchuck, EJD | Conditions
    • Why HIPAA is failing and what you need to know to protect your data [PODCAST]

      The Podcast by KevinMD | Podcast
    • Revolutionizing emergency medicine: Overcoming long-term challenges with innovative solutions for physicians and patients

      Anonymous | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 2 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • What Drug Did FDA Just Approve for COVID?
  • PET Scan for Alzheimer's Dx; Predicting Colon Cancer Survival
  • What Happens When We Classify Kids' Weight as a 'Disease'?
  • Sotagliflozin Gets FDA's Blessing for Heart Failure
  • Cardiorespiratory Monitoring Can Be Telling of Outcomes in Extremely Preterm Infants

Meeting Coverage

  • No Access to Routine Healthcare Biggest Barrier to HPV Vaccination
  • Trial Results Spark Talk of Curing More Metastatic Cervical Cancers
  • Cross-Border Collaboration Improves Survival in Pediatric Leukemia Patients
  • Monoclonal Antibody Reduced Need For Transfusions in Low-Risk MDS
  • Less-Invasive Surgery for Pancreatic Cancer Proves Safe, Effective
  • Most Popular

  • Past Week

    • A patient’s perspective on the diminishing relationship between doctors and patients

      Michele Luckenbaugh | Conditions
    • Unmasking wage disparity in health care: the truth behind the Elmhurst Hospital physician strike

      Kevin Pho, MD | KevinMD
    • Why affirmative action is crucial for health equity and social justice in medicine

      Katrina Gipson, MD, MPH | Policy
    • How electronic health records preserve patients’ legacies in the words of oncologists

      Marc Braunstein, MD, PhD | Physician
    • Unmasking the brutal reality of gun violence in America: a call to action for unity and meaningful change

      Osmund Agbo, MD | Policy
    • Emulating Michael Jordan’s winning mindset: a path to success for health care professionals and entrepreneurs

      Harvey Castro, MD, MBA | Physician
  • Past 6 Months

    • The growing threat to transgender health care: implications for patients, providers, and trainees

      Carson Hartlage | Policy
    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
  • Recent Posts

    • Why doctors aren’t to blame for the U.S. opioid crisis [PODCAST]

      The Podcast by KevinMD | Podcast
    • Raw humanity on night float: inspiring patient encounters and overcoming challenges

      Johnathan Yao, MD, MPH | Physician
    • Is AI the solution for the shortage of nephrologists? ChatGPT weighs in.

      Amol Shrikhande, MD | Tech
    • Unlocking the secrets of cancer conferences: an end-of-life counselor’s journey among pharmaceutical giants

      Althea Halchuck, EJD | Conditions
    • Why HIPAA is failing and what you need to know to protect your data [PODCAST]

      The Podcast by KevinMD | Podcast
    • Revolutionizing emergency medicine: Overcoming long-term challenges with innovative solutions for physicians and patients

      Anonymous | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

How are biosimilar drugs affected by health reform?
2 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...